Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF

Running, not enrolling

Conditions studied: Cystic Fibrosis

In brief

The goal of the study is to examine multiple markers of anthropometrics, body composition, sarcopenia and frailty and compare them to dual energy X-ray absorptiometry (DXA) output, which is considered the current clinical gold-standard tool to measure body composition. The result of this study will provide detailed data regarding the nutrition and body composition within this Cystic Fibrosis population and also provide a baseline evaluation for use of these biomarkers in the future studies including evaluation of nutritional intervention. Further, the study will also include psychosocial and other patient-reported outcomes and medical contributors to understand their contributions to the nutritional failure in the adult advanced lung disease population. Finally, the study will evaluate both established and emerging nutritional and body composition parameters and link them to clinical outcomes in adults with CF across the spectrum of pulmonary function.

Key facts

Study ID: NCT05639556
Run by: Jaeb Center for Health Research
People needed: 300
Starts: 2023-04-20
Expected to finish: 2028-12-01
Last updated by the study team: 2026-03-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Cohort 1: Participants are eligible if their percentage of predicated forced expiratory volume in 1 second (ppFEV1) is <70% during the 12 months prior to enrollment (>50% of measurements, eliminating periods of exacerbation)
Cohort 2: Participants are eligible if their percentage of predicted forced expiratory volume in 1 second (ppFEV1) is 70% or greater during the 12 months prior to enrollment (>50% of measurements, eliminating periods of exacerbation).
Both cohorts match by age, gender, race and CFTR genotype severity.

You may not qualify if…

No prior solid organ transplantation
No initiation of an investigation drug within 28 days prior to and including Baseline Visit.
No initiation of new chronic therapy (e.g., ibuprofen, azithromycin, inhaled tobramycin, Cayston, CFTR modulator, etc.) within 28 days prior to and including Baseline visit.
No acute use of antibiotics (oral, inhaled or IV) or acute use of systemic corticosteroids for respiratory tract symptoms within 14 days prior to and including Baseline visit.
For the BIA sub-study - Individuals with an implanted pacemaker will be excluded.
No initiation of a drug for weight loss (such as a GLP-1 receptor agonist) or bariatric surgery within 6-months prior to and including the Baseline visit.
Patients with continued rapid change or extreme GI symptoms related to weight loss therapy should be excluded at the discretion of the study investigator.

Where it is running

University of Arizona — Tucson, Arizona, United States
University of Arkansas for Medical Sciences (UAMS) — Little Rock, Arkansas, United States
Emory — Atlanta, Georgia, United States
Northwestern University — Chicago, Illinois, United States
University of Iowa — Iowa City, Iowa, United States
University of Kentucky — Lexington, Kentucky, United States
Tulane University — New Orleans, Louisiana, United States
John Hopkins University — Baltimore, Maryland, United States
Massachusetts General Hospital (MGH) — Boston, Massachusetts, United States
Boston Children's Hospital and Brigham and Women's CF Center — Boston, Massachusetts, United States
University of Minnesota — Minneapolis, Minnesota, United States
Washington University School of Medicine (St. Louis) — St Louis, Missouri, United States
Rutgers Health — New Brunswick, New Jersey, United States
New York Medical College (NYMC) — Hawthorne, New York, United States
Northwell LIJ Adult Cystic Fibrosis Center — New Hyde Park, New York, United States
University of Cincinnati — Cincinnati, Ohio, United States
University Hospitals — Cleveland, Ohio, United States
University of Oklahoma Sciences Center — Oklahoma City, Oklahoma, United States
Oregon Health and Science University — Portland, Oregon, United States
University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
Medical University of South Carolina — Charleston, South Carolina, United States
Baylor University — Houston, Texas, United States
University of Virginia Cystic Fibrosis Center — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.